


## WHAT IS CLAIMED IS

1. A compound of formula (I):



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>, provided that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;


R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

$R^5$  is alkyl or  $R^5$  is a direct bond to the carbon at C14;  
 $R^6$  is hydrogen,  $-R^8-OR^7$  or  $-R^8-N(R^7)_2$ ;  
each  $R^7$  is independently selected from the group consisting of hydrogen,  $-R^{10}-OR^9$ ,  $-R^{10}-N(R^9)_2$ , alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;  
each  $R^8$  is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;  
each  $R^9$  is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and  
each  $R^{10}$  is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;  
as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;  
or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in a mixture.

2. The compound of Claim 1 having the following formula (Ia):



wherein:

the A, C or D ring is independently fully saturated or partially saturated;  
C1, C4, C11, C12, C15 and C16 are each independently substituted with

two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

3. The compound of Claim 2 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

4. The compound of Claim 3 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

$R^3$  is selected from the group consisting of  $-R^8-OR^7$ ,  $-R^8-OC(O)R^9$ ,  $-R^{10}-N(R^7)_2$ ,  $-R^{10}-N(R^9)C(O)R^9$ ,  $-R^{10}-N(R^9)S(O)_tR^9$  (where t is 1 or 2),  $-R^{10}-N(R^9)C(NR^9)N(R^9)_2$ , alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

$R^{4a}$  and  $R^{4b}$  are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or  $R^{4a}$  is hydrogen, alkyl, alkenyl or alkynyl and  $R^{4b}$  is a direct bond to the carbon at C16;

or  $R^{4a}$  and  $R^{4b}$  together form alkylidene or haloalkylidene;

$R^5$  is alkyl or  $R^5$  is a direct bond to the carbon at C14;

$R^6$  is hydrogen,  $-R^8-OR^7$  or  $-R^8-N(R^7)_2$ ;

each  $R^7$  is independently selected from the group consisting of hydrogen,  $-R^{10}-OR^9$ ,  $-R^{10}-N(R^9)_2$ , alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each  $R^8$  is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each  $R^9$  is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each  $R^{10}$  is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

5. The compound of Claim 4 wherein:

$R^1$  is  $-OR^7$ ;

$R^2$  is  $-R^8-OR^7$ ;

$R^3$  is  $-R^8-OR^7$ ;

$R^{4a}$  and  $R^{4b}$  are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or  $R^{4a}$  is hydrogen, alkyl, alkenyl or alkynyl and  $R^{4b}$  is a direct bond to the carbon at C16;

or  $R^{4a}$  and  $R^{4b}$  together form alkylidene or haloalkylidene;

$R^5$  is alkyl;

$R^6$  is hydrogen;

each  $R^7$  is independently selected from the group consisting of hydrogen, alkyl, substituted aryl or optionally substituted aralkyl; and

each  $R^8$  is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain.

6. The compound of Claim 5 selected from the group consisting of the following:

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-hydroxyethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-hydroxyethyl)-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-hydroxyethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-3a,4,5,6,7,7a-hexahydro-3H-indene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(4-benzyloxybut-1-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methylenoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(4-hydroxybut-1-en-1-yl)cyclohexyl)-4 $\alpha$ -

hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene; and

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-hydroxyprop-1-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene.

7. The compound of Claim 4 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>3</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

8. The compound of Claim 7 selected from the group consisting of the following:

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-ethylideneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-1,1-dimethyl-2,3,4,5,6,7-hexahydro-1*H*-indene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-aminoethyl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-aminoethyl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-difluoromethyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-difluoromethyleneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-dichloromethyleneoctahydroindene, ammonium chloride salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1 $\beta$ -(propen-2-yl)octahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1 $\beta$ -(propen-2-yl)octahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\alpha$ ,5 $\alpha$ -dihydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(4-dimethylaminobut-2*Z*-en-1-yl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(4-dimethylaminobut-2Z-en-1-yl)-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(ethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(benzyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(cyclopropylmethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(dimethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(dimethyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(methyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(methyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(1-methylpiperidin-4-yl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium diacetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(3-nitrobenzyl)aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -

(piperonyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(pyrrol-2-ylmethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(furfuryl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(pyridin-3-ylmethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-methylpropyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(pyridin-3-ylmethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-hydroxyethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(furfuryl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-dimethylaminoethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-cyclohex-1-en-1-ylethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-morpholin-4-ylethyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(3-methylphenyl)aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(benzyl)aminomethyl-7a $\beta$ -methyl-1-methylenoctahydroindene; and

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-(3-methylphenyl)aminoethyl)-7a $\beta$ -methyl-1-methylenoctahydroindene.

9. The compound of Claim 3 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>3</sup> is selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylklenyl, and optionally substituted heteroarylklenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen,

alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

10. The compound of Claim 9 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>3</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

11. The compound of Claim 10 selected from the group consisting of the following:

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-ethylideneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-dimethylaminoprop-1-enyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-dimethylaminoprop-1-enyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-dimethylaminoprop-1-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(4-dimethylaminobut-1-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-hydroxyethyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-dimethylaminoethyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(cyclohexyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(pyridin-3-ylmethyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(furfuryl)aminomethylcyclohexyl)-4 $\alpha$ -

hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-fluorophenyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(pyridin-3-yl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-methylphenyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(cyclopentyl)aminomethylcyclohexyl)-4 $\alpha$ -aminomethyl-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-fluorobenzyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(1,3-benzodioxol-5-yl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-methylpropyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(cyclohexyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(*N*-phenyl-*N*-methylamino)methylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(pyridin-3-ylmethyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(furfuryl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-hydroxyethyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-methylphenyl)aminomethylcyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(2-dimethylaminoethyl)aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7 $\alpha$  $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(1,3-benzodioxol-5-yl)aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(cyclohexyl)aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(3-trifluoromethylphenyl)aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene; and  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(2-methylpropyl)aminoethyl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt.

12. The compound of Claim 9 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>3</sup> is -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen,

alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

13. The compound of Claim 12, namely, 5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(cyclopentyl)aminomethylcyclohexyl)-4 $\alpha$ -aminomethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium diacetate salt;

14 The compound of Claim 2 wherein:

R<sup>1</sup> is -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene

chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

15. The compound of Claim 13, namely, 5-(1 $\beta$ -methyl-4 $\beta$ -amino-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt.

16. The compound of Claim 4 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>3</sup> is -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2) or -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

17. The compound of Claim 16 selected from the group consisting of the following:

5-(1β-methyl-4β-hydroxy-2β-hydroxymethylcyclohexyl)-4α-(methylsulfonyl)aminomethyl-7aβ-methyl-1-methyleneoctahydroindene;

5-(1β-methyl-4β-hydroxy-2β-hydroxymethylcyclohexyl)-4α-(acetyl)aminomethyl-7aβ-methyl-1-methyleneoctahydroindene; and

5-(1β-methyl-4β-hydroxy-2β-hydroxymethylcyclohexyl)-4α-(guanidino)methyl-7aβ-methyl-1-methyleneoctahydroindene, ammonium chloride salt.

18. The compound of Claim 3 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is selected from the group consisting of -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>3</sup> is -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-OC(O)R<sup>9</sup>;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen,

-R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

19. The compound of Claim 18 selected from the group consisting of the following:

5-(1β-methyl-4β-hydroxy-2β-(pyrrolidin-1-yl)methylcyclohexyl)-4α-hydroxy-7aβ-methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1β-methyl-4β-hydroxy-2β-(2-(4-chlorophenyl)ethyl)cyclohexyl)-4α-hydroxy-7aβ-methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1β-methyl-4β-hydroxy-2β-(2-pyridin-3-ylethyl)cyclohexyl)-4α-hydroxy-7aβ-methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1β-methyl-4β-hydroxy-2β-ethylcyclohexyl)-4α-hydroxy-7aβ-methyl-1-methyleneoctahydroindene;

5-(1β-methyl-4β-hydroxy-2β-(2-(4-ethoxyphenyl)eth-1-en-1-yl)cyclohexyl)-4α-acetoxy-7aβ-methyl-1-methyleneoctahydroindene;

5-(1β-methyl-4β-hydroxy-2β-(2-(pyridin-2-yl)eth-1-en-1-yl)cyclohexyl)-4α-hydroxymethyl-7aβ-methyl-1-methyleneoctahydroindene;

5-(1β-methyl-4β-hydroxy-2β-(2-(pyridin-3-yl)eth-1-en-1-yl)cyclohexyl)-4α-hydroxymethyl-7aβ-methyl-1-methyleneoctahydroindene;

5-(1β-methyl-4β-hydroxy-2β-(hept-1-en-1-yl)cyclohexyl)-4α-hydroxymethyl-7aβ-methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(2-(4-chlorophenyl)ethenyl)cyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-(4-chlorophenyl)prop-2Z-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(3-(4-chlorophenyl)prop-2E-en-1-yl)cyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene;  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(pyrrolidin-1-yl)methylcyclohexyl)-4 $\alpha$ -hydroxymethyl-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt; and  
5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -(morpholin-4-yl)methylcyclohexyl)-4 $\alpha$ -hydroxy-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt.

20. The compound of Claim 4 wherein:

R<sup>1</sup> is -OR<sup>7</sup>;

R<sup>2</sup> is -R<sup>8</sup>-OR<sup>7</sup>;

R<sup>3</sup> is heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl or optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene

chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

21. The compound of Claim 20 selected from the group consisting of the following:

5-(1 $\beta$ -methyl-4 $\beta$ -hydroxy-2 $\beta$ -hydroxymethylcyclohexyl)-4 $\alpha$ -(imidazol-1-yl)methyl-7a $\beta$ -methyl-1-methyleneoctahydroindene;


5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(3-pyridin-3-ylprop-2Z-en-1-yl)-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(3-pyridin-3-ylprop-2E-en-1-yl)-7a $\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-pyrrolidin-1-ylethyl)-7a $\beta$ -methyl-1-methyleneoctahydroindene; and

5-(1 $\beta$ -methyl-2 $\beta$ ,4 $\beta$ -dihydroxycyclohexyl)-4 $\alpha$ -(2-pyrrolidin-1-ylethyl)-7a $\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt.

22. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Claim (I):



wherein:

the A, C or D ring is independently fully saturated, partially saturated or

fully unsaturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>, provided that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;


each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in a mixture.

23. The pharmaceutical composition of Claim 22 wherein the compound of formula (I) is a compound of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated or partially saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;


each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

24. A method of treating an inflammatory condition or disease in a mammal, which method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of formula (I):



wherein:

the A, C or D ring is independently fully saturated, partially saturated or

fully unsaturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>, provided that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl, -R<sup>8</sup>-OR<sup>7</sup>, or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)<sub>t</sub>R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;


each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in a mixture.

25. The method of Claim 24 wherein the compound of formula (I) is a compound of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated or partially saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R<sup>1</sup> is -OR<sup>7</sup> or -N(R<sup>7</sup>)<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of -R<sup>8</sup>-OR<sup>7</sup>, -R<sup>8</sup>-OC(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>7</sup>)<sub>2</sub>, -R<sup>10</sup>-N(R<sup>9</sup>)C(O)R<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)S(O)R<sup>9</sup> (where t is 1 or 2), -R<sup>10</sup>-N(R<sup>9</sup>)C(NR<sup>9</sup>)N(R<sup>9</sup>)<sub>2</sub>, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R<sup>4a</sup> and R<sup>4b</sup> are each independently selected from hydrogen, alkyl, alkenyl or alkynyl;

or R<sup>4a</sup> is hydrogen, alkyl, alkenyl or alkynyl and R<sup>4b</sup> is a direct bond to the carbon at C16;

or R<sup>4a</sup> and R<sup>4b</sup> together form alkylidene or haloalkylidene;

R<sup>5</sup> is alkyl or R<sup>5</sup> is a direct bond to the carbon at C14;

R<sup>6</sup> is hydrogen, -R<sup>8</sup>-OR<sup>7</sup> or -R<sup>8</sup>-N(R<sup>7</sup>)<sub>2</sub>;

each R<sup>7</sup> is independently selected from the group consisting of hydrogen, -R<sup>10</sup>-OR<sup>9</sup>, -R<sup>10</sup>-N(R<sup>9</sup>)<sub>2</sub>, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R<sup>8</sup> is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;


each R<sup>9</sup> is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R<sup>10</sup> is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain.

26. The method of Claim 24 or Claim 25 wherein the inflammatory condition or disease is selected from the group consisting of the following:

arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, osteoarthritis, gout, and synovitis), inflammations of the brain (including multiple sclerosis, Alzheimer's, AIDS dementia, stroke, encephalitis, trauma, and Creutzfeld-Jakob disease), inflammatory bowel disease (including Crohn's disease and ulcerative colitis), irritable bowel syndrome, ischemia-reperfusion injury (including myocardial infarction), sarcoidosis, psoriasis, tissue/organ transplant, graft vs host disease, systemic lupus erythematosus, Type I juvenile diabetes, vasculitis, atherosclerosis, cardiomyopathy, autoimmune myocarditis, atopic dermatitis, asthma, allergy, allergic rhinitis, and chronic obstructive pulmonary disease (including emphysema and bronchitis).

27. A compound of formula (II):



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;

C1, C2, C4, C11, C12, C15 and C16 are each independently substituted with:

(a) one of the following: =O, =C(R<sup>14</sup>)<sub>2</sub>, =C=C(R<sup>14</sup>)<sub>2</sub>, -[C(R<sup>14</sup>)<sub>2</sub>]<sub>n</sub>- (where n is 2 to 6) and -O-[C(R<sup>14</sup>)<sub>2</sub>]<sub>m</sub>-O- (where m is 1 to 6); or

(b) two of the following, which are independently selected: -R<sup>14</sup>, -OR<sup>15</sup> and -N(R<sup>16</sup>)<sub>2</sub>;

C3 is substituted with two of the following, independently selected: -R<sup>14</sup>, -OR<sup>15</sup> and -N(R<sup>16</sup>)<sub>2</sub>;

C5, C8, C9, C10, C13, C14 and C17 are each independently optionally substituted with one of the following: -R<sup>14</sup>, -OR<sup>15</sup> and -N(R<sup>16</sup>)<sub>2</sub>;

R<sup>11</sup> and R<sup>12</sup> are each independently selected from the group consisting of hydrogen, halo, =O, -OR<sup>15</sup>, -N(R<sup>16</sup>)<sub>2</sub> and a C<sub>1-30</sub> organic moiety;

R<sup>13</sup> is -R<sup>14</sup>, -OR<sup>15</sup>, -N(R<sup>16</sup>)<sub>2</sub>, =C(R<sup>14</sup>)<sub>2</sub>, =C=C(R<sup>14</sup>)<sub>2</sub>, -[C(R<sup>14</sup>)<sub>2</sub>]<sub>n</sub>- (where n is 2 to 5) or -O-[C(R<sup>14</sup>)<sub>2</sub>]<sub>m</sub>-O- (where m is 1 to 5);

each R<sup>14</sup> is independently selected from hydrogen, halo and C<sub>1-30</sub> organic moiety where two geminal R<sup>14</sup> groups may together form a ring with the carbon to which they are attached;

each R<sup>15</sup> is independently selected from the group consisting of hydrogen, an oxygen protecting group such that -OR<sup>15</sup> is a protected hydroxy group, a leaving group initiator such that -OR<sup>15</sup> is a leaving group and a C<sub>1-30</sub> organic moiety that may

optionally contain at least one heteroatom selected from the group consisting of boron, halogen, nitrogen, oxygen, phosphorus, silicon and sulfur, where vicinal -OR<sup>15</sup> groups together with the carbons to which they are attached may form a cyclic structure that protects vicinal hydroxy groups and where geminal -OR<sup>15</sup> groups together with the carbon to which they are attached, may form a cyclic structure that protects a carbonyl group;

each R<sup>16</sup> is independently selected from the group consisting of hydrogen, -OR<sup>17</sup>, oxygen (so as to form a nitro or an oxime group), and a C<sub>1-30</sub> organic moiety that may optionally contain at least one heteroatom selected from the group consisting of boron, halogen, nitrogen, oxygen, phosphorus, silicon and sulfur; or

two R<sup>16</sup> groups, together with the nitrogen to which they are attached, form a heterocyclic ring; and

each R<sup>17</sup> is independently selected from hydrogen and a C<sub>1-30</sub> hydrocarbyl; as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in a mixture;

provided, however, that

- (1). C4 can not be substituted with two methyl groups
- (2) R<sup>13</sup> can not be =O or 6-methylhept-2-yl;
- (3) when C17 is substituted with hydrogen, R<sup>13</sup> can not be -OH or -OC(O)R where R is methyl, ethyl, phenyl or cyclohexyl;
- (4) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)H, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub> or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;
- (5) when C1, C2, C4, C11, C12, and C15 are each substituted with two hydrogens, C16 is substituted with hydrogen and hydroxy, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C3 is

substituted with hydrogen and hydroxy, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH or -CH<sub>2</sub>C(O)OCH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HNHCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H, or -C(CH<sub>3</sub>)H-R (where R is 5-methylpiperidin-2-yl);

(6) when C1, C2, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C4 is substituted with two hydrogens or C4 is double bonded to C3, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>CN, R<sup>13</sup> can not be -C(O)OCH<sub>3</sub>;

(7) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is =CHC(O)H, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCHCHC(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(8) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HOC(O)CH<sub>3</sub>;

(9) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is hydroxy, and R<sup>12</sup> is =CHCH<sub>2</sub>OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H, or -C(CH<sub>3</sub>)HCHCHC(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H, -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>)C(CH<sub>3</sub>)<sub>2</sub>H, or -C(CH<sub>3</sub>)HCHC[CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>H]H;

(10) when C1, C2, C4, C11, C12, and C15 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C16 is substituted with two hydrogens or with one hydrogen and hydroxy, R<sup>11</sup> is hydroxy, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>2</sub>OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H, -C(CH<sub>3</sub>)HCH<sub>2</sub>OH, -CH<sub>2</sub>OH, or -C(CH<sub>3</sub>)H-R (where R is 5-methylpiperidin-2-yl);

(11) when C1, C2, C4, C11, C12, C15 and C16 are each substituted

with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is hydroxy, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>C(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H or -C(OH)HCH<sub>3</sub>;

(12) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is hydroxy, and R<sup>12</sup> is -CHCH<sub>2</sub>, R<sup>13</sup> can not be -C(OH)HCH<sub>3</sub>;

(13) when C1, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C2 is substituted with hydrogen and hydroxy, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH, and R<sup>13</sup> is -C(CH<sub>3</sub>)HC(OH)HC(OH)HC(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H, R<sup>12</sup> can not be -CH<sub>2</sub>SH or -CH<sub>2</sub>SSCH<sub>2</sub>R (where R is hydrogen or a C<sub>1-30</sub> organic moiety);

(14) when C1, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C2 is substituted with two hydrogens or with hydrogen and hydroxy, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH or -CH<sub>2</sub>OH, and R<sup>12</sup> is -CH<sub>2</sub>OH, R<sup>13</sup> can not be -CH<sub>2</sub>OH, -C(CH<sub>3</sub>)HC(OH)HC(OH)HC(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H or -C(CH<sub>3</sub>)HC(OH)HC(OH)HC(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(15) when C1, C2, C11, C12 and C15 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C4 is substituted with hydrogen and methyl or with two hydrogens, C5 and C9 are each substituted with hydrogen, C8 and C14 are each substituted with hydrogen or each are substituted with methyl, C10 and C13 are each substituted with methyl, C16 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, R<sup>11</sup> is -C(O)H, and R<sup>12</sup> is -C(O)H, R<sup>13</sup> can not be =C[C(O)OH]CH<sub>2</sub>CH<sub>2</sub>CHC(CH<sub>3</sub>)<sub>2</sub> or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub>;

(16) when C1, C2, C4, C11, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are

each substituted with hydrogen, C10 and C13 are each substituted with methyl, C12 is substituted with hydrogen and hydroxy, R<sup>11</sup> is -CH<sub>2</sub>C(O)OH or -CH<sub>2</sub>C(O)OCH<sub>3</sub>, and R<sup>12</sup> is -NH<sub>2</sub> or -N(CH<sub>3</sub>)<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub> or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OH;

(17) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -NH<sub>2</sub> or -N(CH<sub>3</sub>)<sub>2</sub>, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH or -CH<sub>2</sub>C(O)OCH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub> or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OH;

(18) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and hydroxy, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =NNHC(NH)NH<sub>2</sub>, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>2</sub>C(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)NNHC(NH)NH<sub>2</sub>;

(19a) when C1, C2, C4, C11 and C12 are each substituted with two hydrogens, C3 is substituted with =O, C8, C14 and C17 are each substituted with hydrogen, C9 is substituted with hydrogen or hydroxy, C10 and C13 are each substituted with methyl, C15 is substituted with two hydrogens or C15 is substituted with hydrogen and double bonded to C16, C16 is substituted with hydrogen or hydroxy and is double bonded to C15 or C16 is substituted with =CH<sub>2</sub>OH, R<sup>11</sup> is =O, and R<sup>12</sup> is =CHC(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HC(O)CH<sub>2</sub>C(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(19b) when C1, C2, C4, C11 and C12 are each substituted with two hydrogens, C3 is substituted with =O, C8 and C14 are double bonded to each other, C9 is substituted with hydroxy, C10 and C13 are each substituted with methyl, C15 is substituted with hydrogen and double bonded to C16, C16 is substituted with methoxy and double bonded to C15, C17 is substituted with hydrogen, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OCH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HC(O)CH<sub>2</sub>C(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(20) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with =O, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O,

and R<sup>12</sup> is -CH<sub>2</sub>CN, R<sup>13</sup> can not be -C(O)NHR (where R is 5-trifluoromethyl-2-*t*-butylphenyl) or -C(O)OCH<sub>3</sub>;

(21) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with =O, C8, C9, C14 and C17 are each substituted with hydrogen, C10 is substituted with methyl or -CH<sub>2</sub>OC(O)H, C13 is substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>3</sub> or -CH<sub>2</sub>I, R<sup>13</sup> can not be -C(O)CH<sub>3</sub>;

(22) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with =O, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH, and R<sup>12</sup> is -C(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OH or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

(23) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with =O, C5, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -CN, and R<sup>12</sup> is =O, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCHCHC(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(24) when C1, C2, C4, C12 and C15 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, and C14 are each substituted with hydrogen, C11 is substituted with two hydrogens, hydrogen and hydroxy, or hydrogen and -OC(O)CH<sub>3</sub>, C16 is substituted with two hydrogens or =CH<sub>2</sub>, C17 is substituted with hydrogen, hydroxy or -OC(O)CH<sub>3</sub>, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH, R<sup>13</sup> can not be -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -C(O)CH<sub>3</sub>, cyclopentanone, -C(CH<sub>3</sub>)HOC(O)R (where R is phenyl), -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub>, -C(O)CH<sub>2</sub>OC(O)CH<sub>3</sub> or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(25) when C1, C2, C4, C11, C12 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8 and C9 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C14 is substituted with methyl or -OC(O)CH<sub>3</sub>, C15 is substituted with two hydrogens or =O, C17 is substituted with hydrogen or -OC(O)CH<sub>3</sub>, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)H, R<sup>13</sup>

can not be -C(O)OCH<sub>3</sub>, -C(O)CH<sub>3</sub> or -CH<sub>3</sub>;

(26) when C1, C2, C4, C11, C12, and C15 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, and C14 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C16 is substituted with two hydrogens or forms a double bond with C17, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>CN, R<sup>13</sup> can not be -C(O)CH<sub>3</sub>;

(27) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, C14 and C17 are each substituted with hydrogen, C10 is substituted with hydrogen or -CH<sub>2</sub>C(O)OH, C13 is substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>I or -CH<sub>2</sub>C(O)OCH<sub>3</sub>, R<sup>13</sup> can not be -C(O)CH<sub>3</sub>;

(28) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, C14 and C17 are each substituted with hydrogen, C10 is substituted with hydrogen or -CH<sub>2</sub>C(O)OH, C13 is substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>I, -CHCH<sub>2</sub>, -CCH, -C(O)OCH<sub>3</sub> or -CH<sub>2</sub>OCH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HOC(O)CH<sub>3</sub>

(29) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>NCO, -CH<sub>2</sub>C(O)N<sub>3</sub> or -C(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(30) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C8, C9, and C14 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C17 is substituted with -OC(O)CH<sub>3</sub>, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>CHNNHR (where R is 2,4-dinitrophenyl), R<sup>13</sup> can not be -CH<sub>3</sub>;

(31) when C1, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C2 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH, and R<sup>12</sup> is

-C(O)H, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

(32) when C1, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C2 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH or -C(O)OCH<sub>3</sub>, and R<sup>12</sup> is -C(O)H, -CH<sub>2</sub>SSCH<sub>2</sub>R (where R is hydrogen or a C<sub>1-30</sub> organic moiety), -CH<sub>2</sub>OS(O)<sub>2</sub>CH<sub>3</sub>, or -CH<sub>2</sub>OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HC[OC(O)CH<sub>3</sub>]HC[OC(O)CH<sub>3</sub>]HC(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(33) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -C(O)OH, and R<sup>12</sup> is -C(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OH;

(34) when C1, C2, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C4 is substituted with hydrogen and methyl, C5, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -CH<sub>2</sub>C(O)H, and R<sup>12</sup> is =O, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)C(CH<sub>3</sub>)<sub>2</sub>H;

(35) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, and R<sup>11</sup> and R<sup>12</sup> are both -CHNOCH<sub>3</sub> or -CHNOCH<sub>2</sub>CH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub>;

(36) when C1, C2, C4, C11, C12 and C15 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, C16 is substituted with hydrogen and -OC(O)CH<sub>3</sub>, R<sup>11</sup> is -OC(O)CH<sub>3</sub>, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>2</sub>OC(O)CH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HR (where R is 5-methyl-1-acetylpiriperidin-2-yl);

(37) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and triisopropylsilyloxy, C8, C9,

C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH, -CH<sub>2</sub>C(O)H, -CH<sub>2</sub>CH<sub>2</sub>N<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OS(O)<sub>2</sub>CH<sub>3</sub> or -CH<sub>2</sub>C(O)N<sub>3</sub>, R<sup>13</sup> can not be -C(O)N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>;

(38) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and triisopropylsilyloxy, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH, -CH<sub>2</sub>C(O)H or -CH<sub>2</sub>C(O)Cl, R<sup>13</sup> can not be -C(O)OCH<sub>3</sub>;

(39) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and triisopropylsilyloxy, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, and R<sup>11</sup> and R<sup>12</sup> are both -CHNOCH<sub>3</sub>, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OCH<sub>3</sub>;

(40) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(O)R (where R is 4-nitrophenyl or 3,5-dinitrophenyl), C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -OH, and R<sup>12</sup> is -CH<sub>2</sub>CH<sub>2</sub>OC(O)R (where R is 4-nitrophenyl or 3,5-dinitrophenyl), R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>OC(O)R (where R is 4-nitrophenyl or 3,5-dinitrophenyl) or -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>2</sub>CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(41) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OCH<sub>2</sub>OCH<sub>3</sub>, C5, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -CN, and R<sup>12</sup> is -OH or =O, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCHCHC(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(42) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -CH<sub>2</sub>C(O)OH, R<sup>13</sup> can not be -OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

(43) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with =NNHR (where R is 2,4-dinitrophenyl), C5,

C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, and R<sup>11</sup> and R<sup>12</sup> are both -C(O)OH, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(O)OH;

(44) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OCH<sub>2</sub>R (where R is phenyl), C5, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is -CH<sub>2</sub>C(O)H, and R<sup>12</sup> is =O, R<sup>13</sup> can not be -C(CH<sub>3</sub>)HCH<sub>2</sub>CH<sub>2</sub>C(CH<sub>3</sub>)HC(CH<sub>3</sub>)<sub>2</sub>H;

(45) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -CH<sub>3</sub>, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is =O, and R<sup>12</sup> is -C(O)OH, R<sup>13</sup> can not be -OC(CH<sub>3</sub>)<sub>3</sub>; and

(46) when C1, C2, C4, C11, C12, C15 and C16 are each substituted with two hydrogens, C3 is substituted with hydrogen and -OC(CH<sub>3</sub>)<sub>3</sub>, C5, C8, C9, C14 and C17 are each substituted with hydrogen, C10 and C13 are each substituted with methyl, R<sup>11</sup> is hydroxy, and R<sup>12</sup> is -CH<sub>2</sub>OH, R<sup>13</sup> can not be -OC(CH<sub>3</sub>)<sub>3</sub>.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Claim 27, as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in mixture.

29. A method of treating an inflammatory condition or disease in a mammal, which method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of Claim 27, as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or a pharmaceutically acceptable salt, solvate or prodrug thereof, in isolation or in mixture.